Quisinostat

Quisinostat

Clinical data
ATC code	None
Pharmacokinetic data
Bioavailability	oral
Identifiers
IUPAC name N-Hydroxy-2-[4-({[(1-methyl-1H-indol-3-yl)methyl]amino}methyl)-1-piperidinyl]-5-pyrimidinecarboxamide
Synonyms	JNJ-26481585
PubChem CID	11538455
ChemSpider	9713236
KEGG	D10321
Chemical and physical data
Formula	C21H26N6O2
Molar mass	394.470 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(NO)c1cnc(nc1)N2CCC(CC2)CNCc4c3ccccc3n(c4)C
InChI InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28) Key:PAWIYAYFNXQGAP-UHFFFAOYSA-N

Quisinostat (USAN; development code JNJ-26481585) is an experimental drug candidate for the treatment of cancer. It is a "second generation" histone deacetylase inhibitor with antineoplastic activity. It is highly potent against class I and II HDACs.

It was developed by Janssen Pharmaceuticals and licensed to NewVac LLC.

Preclinical studies show that quisinostat amplifies HDAC-repressed expression of E-cadherin, leading to a reversal of epithelial to mesenchymal transition in tumor cells. Results of a phase I trials in patients with multiple myeloma in combination with bortezomib and dexamethasone were published in 2016.